AI Drug Rescuer Biossil Raises $70M for Repurposed Therapies

Toronto-based Biossil has emerged from its development phase, announcing a substantial $70 million USD equity raise. The company is pioneering a novel approach in pharmaceutical development by leveraging artificial intelligence to identify and advance drug candidates that previously failed in clinical trials. This strategy aims to significantly shorten the drug development timeline and reduce costs associated with bringing new therapies to market.

The significant funding round was supported by a notable roster of investors, including prominent AI-focused entities and established venture capital firms. Backers include OpenAI, Founders Fund, Modern Capital, Staircase Ventures, Golden Ventures, Panache Ventures, Quiet Capital, 137 Ventures, and DRI Healthcare. This diverse investor base underscores the market's confidence in Biossil's innovative model and its potential to disrupt traditional drug discovery.

Biotecnology and pharmaceutical development is a capital-intensive sector, with the average cost to bring a new drug to market estimated to be over $2 billion USD and taking more than a decade. Biossil's model circumvents much of this by acquiring or licensing molecules that have already demonstrated some level of biological activity, thereby de-risking the early stages of development. The company's AI platform is designed to re-evaluate these shelved compounds, identifying new therapeutic applications or optimizing existing ones.

Anthony Mouchantaf, co-founder and CEO of Biossil, previously held a key venture capital role at RBCx, bringing a deep understanding of investment strategy and company building. His co-founder, Chief Scientific Officer Dr. Alexander Mosa, brings a clinical background as a trained internal medicine specialist. This blend of financial acumen and scientific expertise positions Biossil to navigate both the investment and research challenges inherent in the biotech industry. The company has indicated its valuation is in the nine-figure range.

Biotecnology is experiencing a significant influx of capital, driven by advancements in AI and a growing demand for novel treatments across various disease areas. The global biotechnology market is projected to reach hundreds of billions of dollars in the coming years, with AI integration being a key growth driver. Biossil's focus on repurposing failed drug candidates taps into this trend by offering a more efficient pathway to market for potentially life-saving medications.

Currently, Biossil is advancing several drug candidates through clinical trials for conditions such as sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. The company also has a pipeline of nearly a dozen additional therapeutic programs in development. Biossil's operational footprint spans Toronto and the Boston area, employing approximately 30 professionals dedicated to its AI platform and molecule development teams.